News
The day at a glance · 4 min read
Mood · Risk-On
+65
Sentiment, −100 to +100
BMY Dividend Yield
4.35%
Big Pharma & Biotech Pipeline
BMY P/E Multiple
4.4%
Big Pharma & Biotech Pipeline
YTD M&A Volume
$2.5 trillion
Healthcare M&A Activity
Key driverExpanded PBM coverage for obesity drugs and robust M&A activity signal strong sector fundamentals amid pipeline maturation
Daily briefHealthcare· Money365.Market AI ·

Eli Lilly Obesity Coverage Expands; M&A Activity Surges

CVS Caremark adds LLY obesity portfolio to formulary as healthcare M&A reaches $2.5 trillion YTD; Bristol Myers growth portfolio gains momentum

Big Pharma & Biotech Pipeline

Bullish
01BMY
Bristol Myers Squibb ($BMY) has seen its growth portfolio overtake its legacy products, with analysts highlighting four near-term pipeline catalysts and a dividend yield of 4.35%. The company trades at 16x P/E versus the pharma sector average of 24x, though questions remain about long-term valuation despite the attractive 4.4% yield.
02MRNA
Moderna ($MRNA) disclosed Phase II KEYNOTE-942 oncology data for its Intismeran mRNA immunotherapy, advancing its pipeline beyond infectious disease applications.
03PFE
Pfizer ($PFE) continues to attract attention as a dividend stock for long-term holders, while Eli Lilly ($LLY) dominates obesity care discussions with recent CEO comments driving bullish sentiment on Wall Street.

PBM Coverage & Obesity Drugs

Bullish
01LLY
CVS Caremark has moved to cover Eli Lilly's ($LLY) full obesity drug portfolio, including the newly approved oral therapy Foundayo, aligning with other major U.S. pharmacy benefit managers. Coverage spans both Foundayo and injectable products such as Zepbound, widening insurance access across key distribution channels and reshaping the growth and pricing outlook for obesity treatments. The decision positions $LLY as a central player in obesity care with expanded formulary presence that could accelerate adoption. Wall Street has turned increasingly bullish following recent comments from the pharmaceutical titan's CEO addressing the latest hot product in the portfolio.

Healthcare M&A Activity

Bullish
LLY
01
Healthcare M&A activity has surged significantly, with total deal volume reaching $2.5 trillion so far this year according to recent reports. The biotech sector is expected to see increased action alongside other hot areas including casinos and home builders, signaling strong appetite for healthcare consolidation. This robust M&A environment reflects improved financing conditions and strategic interest in pipeline assets across the pharmaceutical and biotech landscape. Analysts anticipate continued dealmaking momentum as companies seek to bolster growth portfolios and address patent cliff pressures.

MedTech & Devices Market Outlook

Bullish

Peripheral Vascular Devices Market 2031

$13.22 billion+5.7% CAGR

Peripheral Vascular Devices Market 2026

$10.02 billion
ABTBSX
01
The global peripheral vascular devices market is projected to reach $13.22 billion by 2031, growing at a CAGR of 5.7% from $10.02 billion in 2026. Growth is fueled by increasing prevalence of vascular disorders like PAD linked to aging, diabetes, obesity, and smoking, with innovations in minimally invasive devices such as drug-coated balloons and next-generation stents boosting clinical outcomes.
02ABT
Abbott ($ABT) remains a focus among medical equipment makers, with analysts noting its position in the vascular devices space.
03BSX
Boston Scientific ($BSX) drew attention from market commentators discussing the best medical equipment makers alongside $ABT and Medtronic, with procedural shifts to ambulatory surgical centers driving market dynamics.

Laboratory & Diagnostics Growth

Bullish

Lab Equipment Services Market 2030

$35.4 billion+14.5% CAGR

Lab Equipment Services Market 2025

$18 billion
TMO
01
The global laboratory equipment services market is set to reach $35.4 billion by 2030, expanding from $18 billion in 2025 with a CAGR of 14.5%. This growth is driven by increased R&D investments, higher healthcare spending, and technological advancements across analytical equipment segments.
02TMO
Thermo Fisher ($TMO) leads analyst picks amid AI demand, cloud growth, and biotech expansion shaping outlooks for the laboratory services sector. The Asia-Pacific region is experiencing the highest growth rate, fueled by robust infrastructure development in China and India, with the comprehensive Gold Support Plan dominating service contract segments.
01UNH
UnitedHealth Group ($UNH) faces a lawsuit filed by Massachusetts alleging the company exaggerated illness severity for Medicaid patients to obtain higher payments. The case focuses on claimed inflation of patient risk scores within the state's Medicaid program, and $UNH has denied any wrongdoing. The lawsuit introduces additional legal and reputational questions that go beyond routine operational updates, raising fresh concerns about Medicaid revenue and investor risk. Despite these challenges, $UNH continues to be compared favorably to CVS Health in dividend growth stock comparisons, with growth rather than yield cited as the deciding factor.

AI & Diagnostics Innovation

Neutral

TEM Q1 Revenue

$348.1 million

TEM Price Target (New)

$64

TEM Price Target (Prior)

$95
01TEM
Tempus AI ($TEM) posted total revenue of $348.1 million in Q1, with H.C. Wainwright reducing its price target to $64 from $95 while retaining a Buy rating following the company's first-quarter results. The company ranks among potential short squeeze stocks according to recent analysis, reflecting strong revenue growth in AI-driven diagnostics and precision medicine.
02TEM
$TEM's performance demonstrates continued momentum in applying artificial intelligence to healthcare data analysis and personalized treatment recommendations.

Investor Positioning

Neutral

High-Growth Dividend Avg Yield

1.50%

Discount to Intrinsic Value

30%
LLYREGNPFE
01
The June 2026 high-growth dividend stocks list targets quality healthcare companies trading approximately 30% below intrinsic value with a 1.50% average yield, highlighting continued investor interest in undervalued pharma and biotech names.
02LLY
Eli Lilly ($LLY) appears on multiple screening lists as investors position for continued obesity drug growth momentum.
03REGN
Regeneron ($REGN) faces scrutiny as one of three Nasdaq 100 stocks flagged for potential risk amid concerns about slowing growth, increasing competition, or unsustainable valuations. Dividend-focused strategies continue to favor established pharma names including Pfizer ($PFE) for long-term holders seeking income stability.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy